miRNA‐483‐3p expression directly correlates with increased EMT and poor prognosis in CRC patients. (A) Immunohistochemistry of xenopatient tumors expressing low or high miRNA‐483‐3p levels with NDRG1 and the indicated human EMT markers (n = 3, magnification: 4×). Scale bar, 50 μm. (B) Heatmap showing the percentage of positive area in tumor sections stained as in (A) and analyzed with imagej software (n = 3). Score was calculated performing deconvolution, by subtracting the hematoxylin and eosin background and setting the same threshold for all samples; values represent percentage of positive area from three different and noncontinuous fields of each slide (mean ± SEM, n ≥ 3 per each xenopatient; miRNA‐483‐3p‐high vs. miRNA‐483‐3p‐low, SNAI2: P = 0.0308; ZEB1: P = 0.0097; E‐Cad: P = 0.0079; YAP: P = 0.0097; NDRG1: P = 0.016). (C) Higher magnifications (10×) of xenopatient tumor sections stained for ZEB1. Red arrowheads indicate adenomatous areas. Scale bar, 0.2 mm (n = 3). (D) Survival curve of grade III and IV quadruple WT colorectal cancer patients (TCGA cohort) displaying normal/low miRNA‐483‐3p levels (miRNA‐483‐low, n = 24) or miRNA‐483‐3p overexpression (miRNA‐483‐high, n = 13; **, P = 0.0085; Mantel–Cox).